A phase I/Ib study of trametinib (GSK1120212) alone and in combination with gemcitabine in Japanese patients with advanced solid tumors
- 400 Downloads
Background Trametinib is an inhibitor of MEK1/MEK2 activation and kinase activity. In order to evaluate the safety, tolerability, pharmacokinetics, and preliminary efficacy of single-agent trametinib (part 1) and trametinib in combination with gemcitabine (part 2), we undertook the first clinical study of this combination in Japanese patients with cancer and herein report our results. Methods In part 1, 13 patients with advanced solid tumors were enrolled into 3 dose cohorts, receiving trametinib once daily at a dose of 1.0, 2.0, or 3.0 mg. In part 2, 5 patients with pancreatic cancer received trametinib (2.0 mg once daily) in combination with gemcitabine (1000 mg/m2). Results In part 1, a dose-limiting toxicity was observed in a patient in the 2.0-mg dose cohort, but the maximum tolerated dose was not reached at doses up to 3.0 mg daily. The best overall response was a PR in 1 patient, and 6 patients had SD. In part 2, the combination of trametinib and gemcitabine was tolerated for a short period of time. However, serious interstitial lung disease (ILD) was observed in 3 of 5 patients 4 weeks or more after the start of the treatment, including 1 fatal case. Three patients achieved a PR, and 2 patients had SD. The most common adverse event was rash (85 % in part 1 and 100 % in part 2). Conclusions Trametinib monotherapy was tolerable in Japanese patients with cancer. However, the combination of trametinib plus gemcitabine carried a higher risk as compared with monotherapy, during which no ILD was observed. (ClinicalTrials.gov number, NCT01324258.)
KeywordsMEK inhibitor Trametinib Gemcitabine Japanese Solid tumors Pancreatic cancer
We thank the patients who participated in the MEK114784 study and their families, the MEK114784 study investigators, and the nurses, coordinators, and other study staff who contributed to the study. This study was funded by GlaxoSmithKline. Writing/editorial support was provided Anne Marie Corgan at SciMentum and was funded by GlaxoSmithKline.
Compliance and ethical standards
Conflicts of interest
Dr. Nakagawa reports research grants to their institution from GlaxoSmithKline K.K., and Eli Lilly Japan K.K., during the conduct of the study; personal fees for speaking engagements from GlaxoSmithKline K.K., outside the submitted work. Dr. Nagashima reports research grants to their institution from GlaxoSmithKline, during the conduct of the study; research grants to their institution from GlaxoSmithKline, Chugai Pharmaceutical Co., Eli Lilly Japan, Bayel Yakuhin, OncoTherapy Science, Novartis Pharma, Yakult Honsha Co., Ono Pharmaceutical Co., Taiho Pharmaceutical Co., Takeda Pharmaceutical Company, Merck Serono Co., Sanofi, Shionogi & Co., Sumitomo Dainippon Pharma Co., Kyowa Hakko Kirin Co, Zeria Pharmaceutical Co, and Daiichi Sankyo Co., personal fees for lectures from Chugai Pharmaceutical Co., Takeda Pharmaceutical Company, Taiho Pharmaceutical Co., and Shionogi & Co., personal fees for consulting from Janssen Pharmaceutical Co., outside the submitted work. Dr. Kurata reports research grants to their institution from GlaxoSmithKline, during the conduct of the study; personal fees for speaking engagements from AstraZeneca, Eli Lilly, Boehringer Ingelheim, Taiho, Chugai, and Pfizer, outside the submitted work. Dr. Fujisaka reports research grants to their institution from GlaxoSmithKline, AstraZeneca K.K., Bristol-Myers Squibb, Novartis Pharma K.K., and MSD K.K., during the conduct of the study; personal fees for lectures from Bayer HealthCare, Chugai Pharmaceutical Co. Ltd, Ono Pharmaceutical Co. Ltd, Taiho Pharmaceutical Co. Ltd, Daiichi Sankyo Co. Ltd, Pfizer Japan Inc., Takeda Pharmaceutical Co. Ltd, Eli Lilly Japan K.K., Sanofi K.K., Yakult Honsha Co. Ltd, and Janssen Pharmaceutical K.K., research grants to their institution from AstraZeneca K.K., MSD K.K., Novartis Pharma K.K., and Bristol-Myers Squibb, outside the submitted work. Dr. Okamoto reports research grants to their institution from GlaxoSmithKline, during the conduct of the study. Mr. Nishimura and Mr. Mukaiyama report that they are employees of and stock owners of GlaxoSmithKline. Mr. Matsushita reports that he is an employee of GlaxoSmithKline K.K. Dr. Furuse reports grants from GlaxoSmithKline, during the conduct of the study; grants from Ono pharmaceutical Co., Oncotherapy Science, and Takeda Bio Development Center Ltd, grants and personal fees from Taiho pharmaceutical Co., Eli Lilly Japan, Bayer pharmaceutical Co., and Yakult, personal fees from Chugai pharmaceutical Co., Novartis, Eisai, Kyowa Hakko, and Zeria Pharmaceutical Co., outside the submitted work. Drs. Kitamura and Okamoto report grants to their institutions from GlaxoSmithKline, during the conduct of the study. Drs. Kasuga, Shimizu, Naruge, Nishina, and Takasu have nothing to disclose.
Informed consent was obtained from all individual participants included in the study.
All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.
- 2.Davies H, Bignell GR, Cox C, Stephens P, Edkins S, Clegg S, Teague J, Woffendin H, Garnett MJ, Bottomley W, Davis N, Dicks E, Ewing R, Floyd Y, Gray K, Hall S, Hawes R, Hughes J, Kosmidou V, Menzies A, Mould C, Parker A, Stevens C, Watt S, Hooper S, Wilson R, Jayatilake H, Gusterson BA, Cooper C, Shipley J, Hargrave D, Pritchard-Jones K, Maitland N, Chenevix-Trench G, Riggins GJ, Bigner DD, Palmieri G, Cossu A, Flanagan A, Nicholson A, Ho JW, Leung SY, Yuen ST, Weber BL, Seigler HF, Darrow TL, Paterson H, Marais R, Marshall CJ, Wooster R, Stratton MR, Futreal PA (2002) Mutations of the BRAF gene in human cancer. Nature 417:949–954CrossRefPubMedGoogle Scholar
- 4.Hanlon L, Avila JL, Demarest RM, Troutman S, Allen M, Ratti F, Rustgi AK, Stanger BZ, Radtke F, Adsay V, Long F, Capobianco AJ, Kissil JL (2010) Notch1 functions as a tumor suppressor in a model of K-ras-induced pancreatic ductal adenocarcinoma. Cancer Res 70:4280–4286PubMedCentralCrossRefPubMedGoogle Scholar
- 10.Ohren JF, Chen H, Pavlovsky A, Whitehead C, Zhang E, Kuffa P, Yan C, McConnell P, Spessard C, Banotai C, Mueller WT, Delaney A, Omer C, Sebolt-Leopold J, Dudley DT, Leung IK, Flamme C, Warmus J, Kaufman M, Barrett S, Tecle H, Hasemann CA (2004) Structures of human MAP kinase kinase 1 (MEK1) and MEK2 describe novel noncompetitive kinase inhibition. Nat Struct Mol Biol 11:1192–1197CrossRefPubMedGoogle Scholar
- 12.Infante JR, Fecher LA, Falchook GS, Nallapareddy S, Gordon MS, Becerra C, DeMarini DJ, Cox DS, Xu Y, Morris SR, Peddareddigari VG, Le NT, Hart L, Bendell JC, Eckhardt G, Kurzrock R, Flaherty K, Burris HAI, Messersmith WA (2012) Safety, pharmacokinetic, pharmacodynamic, and efficacy data for the oral MEK inhibitor trametinib: a phase 1 dose-escalation trial. Lancet Oncol 13:773–781CrossRefPubMedGoogle Scholar
- 13.National Cancer Institute (2006) Common Terminology Criteria for Adverse Events (CTCAE) v3.0. In: http://ctep.cancer.gov/protocolDevelopment/electronic_applications/docs/ctcaev3.pdf. Accessed 03/08 Sept 2014
- 14.Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, Dancey J, Arbuck S, Gwyther S, Mooney M, Rubinstein L, Shankar L, Dodd L, Kaplan R, Lacombe D, Verweij J (2009) New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 45:228–247CrossRefPubMedGoogle Scholar
- 15.GlaxoSmithKline (2014) Mekinist (trametinib tablets): US prescribing information. In: http://www.accessdata.fda.gov/drugsatfda_docs/label/2014/204114s001lbl.pdf. Accessed 10 Jan 2014
- 16.Infante JR, Papadopoulos KP, Bendell JC, Patnaik A, Burris HA III, Rasco D, Jones SF, Smith L, Cox DS, Durante M, Bellew KM, Park J, Le N, Tolcher AW (2013) A phase 1b study of trametinib, an oral Mitogen-activated protein kinase kinase (MEK) inhibitor, in combination with gemcitabine in advanced solid tumours. Eur J Cancer 49:2077–2085CrossRefPubMedGoogle Scholar
- 17.Infante JR, Somer BG, Park JO, Li CP, Scheulen ME, Kasubhai SM, Oh DY, Liu Y, Redhu S, Steplewski K, Le N (2014) A randomised, double-blind, placebo-controlled trial of trametinib, an oral MEK inhibitor, in combination with gemcitabine for patients with untreated metastatic adenocarcinoma of the pancreas. Eur J Cancer 50:2072–2081CrossRefPubMedGoogle Scholar
- 18.Azuma A, Kudoh M (2007) High prevalence of drug-induced pneumonia in Japan. J Med Assoc J 50(5):405–411Google Scholar
- 19.Falchook GS, Lewis KD, Infante JR, Gordon MS, Vogelzang NJ, DeMarini DJ, Sun P, Moy C, Szabo SA, Roadcap LT, Peddareddigari VG, Lebowitz PF, Le NT, Burris HAI, Messersmith WA, O’Dwyer PJ, Kim KB, Flaherty K, Bendell JC, Gonzalez R, Kurzrock R, Fecher LA (2012) Activity of the oral MEK inhibitor trametinib in patients with advanced melanoma: a phase 1 dose-escalation trial. Lancet Oncol 13:782–789PubMedCentralCrossRefPubMedGoogle Scholar
- 20.GlaxoSmithKline (2013) Study of GSK1120212 plus gemcitabine vs placebo plus gemcitabine in metastatic pancreatic cancer. In: ClinicalTrials.gov [Internet]. Bethesda: National Library of Medicine (US). http://clinicaltrials.gov/show/NCT01231581. Accessed 30 Sept 2014
- 21.Ueno H, Ioka T, Ikeda M, Ohkawa S, Yanagimoto H, Boku N, Fukutomi A, Sugimori K, Baba H, Yamao K, Shimamura T, Sho M, Kitano M, Cheng AL, Mizumoto K, Chen JS, Furuse J, Funakoshi A, Hatori T, Yamaguchi T, Egawa S, Sato A, Ohashi Y, Okusaka T, Tanaka M (2013) Randomized phase III study of gemcitabine plus S-1, S-1 alone, or gemcitabine alone in patients with locally advanced and metastatic pancreatic cancer in Japan and Taiwan: GEST study. J Clin Oncol 31:1640–1648CrossRefPubMedGoogle Scholar